Phase 2 Evaluation of Topotecan Administered on a 3-Day Schedule in the Treatment of Platinum- and Paclitaxel-Refractory Ovarian Cancer

By Markman M.   Kennedy A.   Webster K.   Kulp B.   Peterson G.   Belinson J.  

Gynecologic Oncology, Vol. 79, Iss. 1, 2000-10 ,pp. : 116-119

Elsevier

Access to resources Recommend Favorite

Phase II Evaluation of 24-h Continuous Infusion Topotecan in Recurrent, Potentially Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

By Markman M.   Blessing J.A.   Alvarez R.D.   Hanjani P.   Waggoner S.   Hall K.  

Gynecologic Oncology, Vol. 77, Iss. 1, 2000-04 ,pp. : 112-115

Elsevier

Access to resources Recommend Favorite

A Phase I/II Study of Topotecan in Combination with Carboplatin in Recurrent Epithelial Ovarian Cancer

By Bolis G.   Scarfone G.   Sciatta C.   Polverino G.P.   Rosa C.   Guarnerio P.   Parazzini F.  

Gynecologic Oncology, Vol. 83, Iss. 3, 2001-12 ,pp. : 477-480

Elsevier

Access to resources Recommend Favorite

High-Dose Topotecan, Melphalan, and Cyclophosphamide (TMC) with Stem Cell Support: A New Regimen for the Treatment of Advanced Ovarian Cancer

By Donato M.L.   Gershenson D.M.   Wharton J.T.   Ippoliti C.M.   Aleman A.S.   Bodurka-Bevers D.   Bevers M.W.   Burke T.W.   Levenback C.F.   Wolf J.K.   Freedman R.S.   Bast R.C.   Gajewski J.L.   Champlin R.E.  

Gynecologic Oncology, Vol. 82, Iss. 3, 2001-09 ,pp. : 420-426

Elsevier

Access to resources Recommend Favorite

Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial

By Simon Thorsten   Längler Alfred   Harnischmacher Urs   Frühwald Michael   Jorch Norbert   Claviez Alexander   Berthold Frank   Hero Barbara  

Journal of Cancer Research and Clinical Oncology, Vol. 133, Iss. 9, 2007-09 ,pp. : 653-661

Springer Publishing Company

Access to resources Recommend Favorite